Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201133 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4EPKMHPGDALOX12 | |
| SCHEMBL6168920 | 0.88 | ALDH1A1 (0.37) | ALDH1A1KDM4EPKMHPGDALOX12 | |
| SCHEMBL25516367 | 0.76 | HTR2C (0.46) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20323475 | 0.75 | SLC18A3 (0.38) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL8177567 | 0.75 | DDB1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3584879 | 0.75 | DDB1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20323351 | 0.75 | SLC18A3 (0.38) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL16796843 | 0.75 | DDB1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19511368 | 0.73 | ESR1 (0.41) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL5051433 | 0.72 | ESR1 (0.51) | KDM4EMEN1KMT2APRCPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129071-B1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | BAYER CROPSCIENCE AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-20030130125-A1 | Phenyl-substituted cyclic enaminones | FISCHER REINER (DE) | 2003-07-10 | — | — | US | claimed |
| EP-1129071-A1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | Bayer Aktiengesellschaft (DE) | 2001-09-05 | — | — | EP | claimed |
| WO-2000027812-A1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| EP-4486743-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-01-08 | — | — | EP | disclosed |
| CN-118765280-A | RIP1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2023160638-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-08-31 | — | — | WO | disclosed |
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| EP-1129071-B1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | BAYER CROPSCIENCE AG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20030130125-A1 | Phenyl-substituted cyclic enaminones | FISCHER REINER (DE) | 2003-07-10 | — | — | US | disclosed |
| US-6455472-B1 | HERBICIDES, ACARICIDES, NEMATICIDES AND INSECTICIDES FOR CROPS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-24 | — | — | US | disclosed |
| EP-1129071-A1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | Bayer Aktiengesellschaft (DE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027812-A1 | PHENYL-SUBSTITUTED CYCLIC ENAMINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130125-A1 | Phenyl-substituted cyclic enaminones | DDT, CYP19A1, KCNA1 | ALDH1A1 410/4885KDM4E 527/4885PKM 12/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | ALDH1A1 4611/4885KDM4E 3746/4885PKM 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.